drugset / Trial / NCT04834973
A Trial of Tigilanol Tiglate in Combination With Pembrolizumab in Stage IIIB to IV M1c-melanoma
NaSingle-groupOpen-labelTreatment
Summary
A Phase Ib/IIa, multicentre, open label, dose-escalation study to evaluate the safety, tolerability, and preliminary effectiveness of intratumoural tigilanol tiglate in combination with intravenous pembrolizumab in adult patients with unresectable, Stage IIIB to IV M1c melanoma.
Timeline
- Start
- 2021-05-07
- Primary completion
- 2022-07-12
- Completion
- 2022-07-12
Outcome
Outcome not reported
Stopped (Enrollment): “Insufficient Patient Recruitment Rates”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pembrolizumab | Monoclonal antibody | 200 mg | Intravenous |
| Subject | Tigilanol Tiglate | Small molecule | 0.6 mg/m2 | Other |
| Subject | Tigilanol Tiglate | Small molecule | 1.2 mg/m2 | Other |
| Subject | Tigilanol Tiglate | Small molecule | 2.4 mg/m2 | Other |